Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9581238 | 0.98 | CYP2A6 (0.42) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| Formic Acid SCHEMBL28208544 | 0.88 | CYP2A6 (0.42) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28318294 | 0.83 | DYRK1A (0.46) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6733 | 0.81 | CYP2A6 (0.50) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28844051 | 0.80 | MAOB (0.45) | KDM4EMAOAHSD17B10MEN1ALDH1A1 | |
| Ethoxycarbonyl Group SCHEMBL28245391 | 0.79 | CHRM2 (0.41) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| Formaldehyde SCHEMBL28085404 | 0.76 | CYP2A6 (0.50) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29756248 | 0.75 | DYRK1A (0.50) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2149910 | 0.73 | CYP2A6 (0.54) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29329001 | 0.73 | CYP2A6 (0.45) | CYP2A6KDM4ECYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-108129430-A | A kind of synthetic method of Li Tasite intermediates | 重庆圣华曦药业股份有限公司 | 2018-06-08 | — | — | CN | claimed |
| US-12613246-B2 | Fluorescent probe and protein labeling method | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12404257-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-12365661-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | SHOUYAO HOLDINGS BEIJING CO LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-12344591-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250188049-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2025-06-12 | — | — | US | disclosed |
| EP-3647315-B9 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-120040398-A | Advantageous benzofuran compositions for mental disorders or mental enhancement | 泰科根公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-0355827-B1 | Hydantoin derivatives | MOCHIDA PHARM CO LTD (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-RE35279-E | ALDOSE REDUCTASE INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-18 | — | — | US | disclosed |
| EP-0693475-A1 | 1-Phenyl-3-dimethylamino-propane derivatives having pharmacological activity | Grünenthal GmbH (DE) | 1996-01-24 | — | — | EP | disclosed |
| EP-0560554-A2 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| US-5202339-A | Hypoglycemic, hypolipedemic agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| US-5169860-A | Benzofuran or benzothiophene arylsulfonylureas | ELI LILLY AND COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| US-5004751-A | Antidiabetic agents; aldoe reductase inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| WO-1990002126-A1 | HYDANTOIN DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355827-A2 | Hydantoin derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | CYP2A6 3751/4885KDM4E 2609/4885CYP3A4 3671/4885 |
| US-12404257-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | CYP2A6 884/4885KDM4E 1815/4885CYP3A4 1609/4885 |
| US-12613246-B2 | Fluorescent probe and protein labeling method | CYFIP1, IK, CYFIP2 | CYP2A6 4348/4885KDM4E 4624/4885CYP3A4 4487/4885 |
| US-12344591-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | CYP2A6 884/4885KDM4E 1815/4885CYP3A4 1609/4885 |
| US-20250221979-A1 | NOVEL HETEROCYCLIC COMPOUND | MAPT, MNAT1, MAT2A | CYP2A6 704/4885KDM4E 3698/4885CYP3A4 1605/4885 |
| US-12365661-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | CYP2A6 884/4885KDM4E 1815/4885CYP3A4 1609/4885 |
| US-20250188049-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | CYP2A6 884/4885KDM4E 1815/4885CYP3A4 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.